MOESM1 of Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

Additional file 1: Supplemental Methods. Randomization. Blood and urine collection for PK/PD analyses. Blood and urine collection for analysis of safety laboratory parameters. Analysis of vital signs. Figure S1. Dose-normalized a) Cmax and b) AUCinf following SAD of IR and MR PF-06650833 formulations. Figure S2. Dose-normalized a) Cmax and b) AUCtau (day 14) following MAD of IR and MR PF-06650833 formulations.